(Q43034847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

eradication of infectious diseases

24 January 2020

main subject

liver cirrhosis

0 references

1 reference

1 reference

hepatocellular carcinoma

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

José Velosa

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Fátima Serejo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Joana Nunes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Helena Glória

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

5 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

1853-1861

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21374066%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10620-011-1621-2

24 January 2020

exact match

0 references

cites work

Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS10620-011-1621-2

21 January 2018

12 December 2020

Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study

1 reference

12 December 2020

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

12 December 2020

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

12 December 2020

Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy

1 reference

12 December 2020

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

12 December 2020

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients

1 reference

12 December 2020

Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients

1 reference

12 December 2020

Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C

1 reference

12 December 2020

Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C

1 reference

12 December 2020

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group

1 reference

12 December 2020

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

12 December 2020

A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.

1 reference

12 December 2020